🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

26 results for “cetuximab” Clear

  1. Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  2. CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  3. CETUXIMAB

    Disc Medicine

    oral squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL

    Incyte Biosciences Distribution B.V.

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  5. Monalizumab, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, CETUXIMAB

    AstraZeneca AB

    Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

    phase 3 small molecule active

    1 trial

  6. mCapOX plus Cetuximab

    China SXT Pharmaceuticals

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  7. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb / Pfizer EEIG

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  8. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracile Teva 250 mg/5 ml soluzione per infusione, CARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione, CETUXIMAB, PEMBROLIZUMAB, Cisplatino Teva Italia 0,5 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

    phase 2 small molecule active

    1 trial

  9. C225 (cetuximab)

    First Tracks Biotherapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  10. CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  11. CETUXIMAB , MK-1084, MK-1084, MK-1084, MK-1084

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  12. CETUXIMAB, FOLINIC ACID, FLUOROURACIL, IRINOTECAN

    Fondazione Telethon ETS

    ADCC, Colorectal Cancer

    phase 2 small molecule active

    1 trial

  13. Cetuximab

    Solid Biosciences

    Head and Neck Neoplasm

    phase 2 small molecule completed

    1 trial

  14. Cetuximab

    United Therapeutics Europe Ltd

    BRAF V600E Negative

    phase 2 mab active

    1 trial

  15. DOCETAXEL , PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , CETUXIMAB, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  16. ENCORAFENIB , CETUXIMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  17. IRINOTECAN, FLUOROURACIL , CETUXIMAB , ENCORAFENIB , SODIUM FOLINATE

    Fondazione Telethon ETS

    Patients affected by mCRC harbouring BRAF V600E

    phase 2 small molecule active

    1 trial

  18. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CETUXIMAB, olomorasib

    Eli Lilly Co.

    KRAS G12C-Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  19. LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB

    Novartis Ophthalmics Europe

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  20. MK-1022, -, MK-1084, MK-1084, MK-2870, MK-1084, CETUXIMAB , MK-1084

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  21. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  22. PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  23. cetuximab (Erbitux)

    China SXT Pharmaceuticals

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  24. A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer

    Boehringer Ingelheim International GmbH

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources